ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Thymic B Cells: A Means to Control Regulatory Tolerance

C. LeGuern1, S. Germana1, N. Feeney1, Z. Wang2, N. Tanimine1, C. Huang3, C. Rickert1, J. Markmann1

1Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Charlestown, MA, 2University of Colorado Denver, Aurora, CO, 3Surgery, University of Colorado Denver, Aurora, CO

Meeting: 2020 American Transplant Congress

Abstract number: 615

Keywords: B cells, MHC class II, Thymic tolerance

Session Information

Session Name: Lymphocyte Biology: Signaling, Co-Stimulation, Regulation

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:15pm-4:27pm

Location: Virtual

*Purpose: Therapies involving CD4 regulatory T cells (Tregs) are promising approaches to mitigate graft rejection and autoimmunity. Understanding of the activation mechanisms that initiate Treg development and potentiates suppression will facilitate Treg application. Recent studies indicate that B cells from the thymic medulla express incomparably high levels of MHC class II (MHC-II) molecules, suggesting a prominent role in antigen presentation. Medullary B cells also cluster around Treg precursors going under final developmental steps. We thus hypothesized that thymic B cells preferentially present peptides on MHC-II molecules to maturing Treg precursors.

*Methods: We first derived the MHC-II IAα fl/fl mouse on the C57BL/6 background (IAαβb, IE0). This mouse was then crossed to mouse lines expressing Cre recombinase at early pro-B stage (Mb1-Cre) or at the pro-pre B transition (CD19-Cre). IAα gene disruption was examined in the resulting mb1 and CD19 lines by DNA-PCR and MHC-II IAb expression was followed by flowcytometry (FCM). We measured the frequencies and numbers of effector and regulatory CD4 T cells, CD8 T cells and B cells isolated from blood and thymus. Lymphocyte activation was evaluated by FCM for expression of MHC-II, CD69, CD44 and CD86. Phosflow was also performed to document lymphocyte activation via kinase signaling (pS6, pAKT and pERK).

*Results: MHC-II gene extinction in B cells at early (mb1 mutant) or later (CD19 mutant) developmental stages showed differential phenotypes revealing the importance of timing and dosage of B cell MHC-II expression on the development and homeostasis of B and CD4+ T lymphocytes. Disruption of MHC-II gene expression at the pro-B cell stage (mb1 mutant) led to normal counts of blood B cells which were all MHC-IIneg. This phenotype remained stable over time. Thymic B cells exhibited an activated phenotype (CD69hi, CD44hi, CD86hi), similar to that of wildtype B cells. Conversely, lack of MHC-II expression at later pro-pre B cell transition stage (CD19 mutant) led to low counts of MHC-IIneg B cells that recovered MHC-II expression over time. Thymic B cells from CD19 mutants harbored a resting phenotype (CD69low, CD44low, CD86low). Together, these data indicate that early MHC-II expression has qualitative and quantitative impacts on B cell development and fitness. Interestingly, both mutants showed lower frequencies of circulating B cells among CD45+ lymphocytes. This defect was compensated by a spike in CD4+ T production, suggesting that MHC-II+ B cells impact on CD4+ T cell homeostasis. Accordingly, pilot studies on thymic CD4+ Tregs from MHC-II deficient mice showed significant reduction in TCR fitness during activation.

*Conclusions: In sum, we here provide evidence in support of a critical role of antigen-presentation by B cells in both B cell development and Treg maturation.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

LeGuern C, Germana S, Feeney N, Wang Z, Tanimine N, Huang C, Rickert C, Markmann J. Thymic B Cells: A Means to Control Regulatory Tolerance [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/thymic-b-cells-a-means-to-control-regulatory-tolerance/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences